Fundz

Fortitude Biomedicines raises $13M in Seed funding to advance antibody-based therapies for autoimmune diseases and cancer, co-led by K2 Bio Partners and SHAC.

PRIVATEJan 26, 2026

Amount Raised

$13 Million

Round Type

Seed

WalthamBiotechnologyHealth CareTherapeutics

Investors

Shanghai Healthcare Angel CapitalElikon VentureEverjoy FortuneTaihill VentureK2 Bio Partners

Description

Fortitude Biomedicines, Inc. announced the closing of a $13 million Seed financing to advance their novel antibody-based therapies. The funding will support their lead immune cell targeting biologic program through IND enabling studies. Co-led by K2 Bio Partners and Shanghai Healthcare Angel Capital, with participation from additional investors

Quick answer

Fortitude Biomedicines raised $13 Million in a Seed round, dated January 26, 2026. Investors: Shanghai Healthcare Angel Capital, Elikon Venture, Everjoy Fortune, Taihill Venture and K2 Bio Partners. Fortitude Biomedicines is based in Waltham, Massachusetts, United States.

How much did Fortitude Biomedicines raise?
Fortitude Biomedicines raised $13 Million in a Seed round on January 26, 2026.
Who invested in Fortitude Biomedicines?
Shanghai Healthcare Angel Capital, Elikon Venture, Everjoy Fortune, Taihill Venture and K2 Bio Partners are named as investors in this round.
What does Fortitude Biomedicines do?
Fortitude Biomedicines is a leading biopharmaceutical company focused on immune cell targeting biologics and molecular glue payload–enabled antibody–drug conjugates (ADCs) for the treatment of a wide range of autoimmune..
Where is Fortitude Biomedicines based and how big is it?
Fortitude Biomedicines is based in Waltham, Massachusetts, United States. Fundz records about 7 employees.
Who are the decision-makers at Fortitude Biomedicines?
Fundz holds 1 contact at Fortitude Biomedicines, including the Director of Operations & Corporate Development. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Fortitude Biomedicines that raised within 45 days of this round, from Fundz verified event records.

  • Combat Medical raised $3.5M (Series A) on March 12, 2026.
  • GenSight Biologics raised $2M (Post-IPO Equity) on March 10, 2026.
  • Cognito Therapeutics raised $105M (Series C) on March 5, 2026.
  • NexCure raised $19M (Series A) on March 5, 2026.
  • Prolium Bioscience raised $50M (Series A) on March 5, 2026.
  • Os Therapies raised $2M on March 4, 2026.

Who to call at Fortitude Biomedicines, and when

A new round usually means Fortitude Biomedicines is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Fortitude Biomedicines raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Fortitude Biomedicines, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Fortitude Biomedicines. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Fortitude Biomedicines

Location

Waltham, Massachusetts, United States

About

Fortitude Biomedicines is a leading biopharmaceutical company focused on immune cell targeting biologics and molecular glue payload–enabled antibody–drug conjugates (ADCs) for the treatment of a wide range of autoimmune diseases and cancers. The company harnesses proprietary technology to unlock the ability to precisely target diseases while engaging the body’s own biology. Fortitude's innovative GLUE-DACTM platform is designed to expand the therapeutic window of ADCs and overcome resistance mechanisms. The founding team includes experts with extensive experience in translational research and drug development.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Fortitude Biomedicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsWendi N., Director of Operations & Corporate Deve…See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Fortitude Biomedicines's next move

See what Strategic adds

Fortitude Biomedicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.